By using samples from primary breast tumors, researchers identified that immune cells carrying somatic mutations in CH driver genes were infiltrating the tumor microenvironment (TME).77 Additionally, there is evidence that patients with solid tumors with CH, at least those with TET2 or DNMT3A variants, experience elevated levels of lymphocyte invasion in the TME.78 Given that these mutant immune cells are entering the TME, it is reasonable to predict that they might be disturbing the intricate balance of immunity and eliciting a direct effect on the growth and progression of the tumor. This evidence concerns the gene TET2 and neoplasm.